BRAF mutations have been detected in 7 to 8% of cancers, and the V600E mutation accounts for >90% of BRAF mutations.[11] KRAS mutations are negative prognostic factors for the efficacy of anti-epidermal growth factor receptor therapy for advanced CRC, which means patients benefit little from anti-epidermal growth factor receptor therapy.[12,13]. This evidence concerns the gene KRAS and colorectal carcinoma.